Twist Bioscience Corporation (NASDAQ:TWST) shares fell to a low of $104.43 before closing at $106.77. Intraday shares traded counted 0.55 million, which was 34.98% higher than its 30-day average trading volume of 842.07K. TWST’s previous close was $105.00 while the outstanding shares total 48.71M. The stock’s Relative Strength Index (RSI) is 50.93, with weekly volatility at 6.06% and ATR at 7.75. The TWST stock’s 52-week price range has touched low of $35.50 and a $214.07 high. The stock traded higher over the last trading session, gaining 1.69% on 06/09/21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Investors have identified the Diagnostics & Research company Twist Bioscience Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $5.21 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Twist Bioscience Corporation (TWST) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TWST, the company has in raw cash 399.33 million on their books with 3.17 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 608.0 million total, with 40.44 million as their total liabilities.
TWST were able to record -61.51 million as free cash flow during the 08/05/2021 quarter of the year, this saw their quarterly net cash flow reduce by 306.61 million. In cash movements, the company had a total of -49.48 million as operating cash flow.
Potential earnings growth for Twist Bioscience Corporation (TWST)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/05/2021 quarter of the year, Twist Bioscience Corporation recorded a total of 31.2 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 38.16% coming in sequential stages and their sales for the 08/05/2021 quarter increasing by 9.75%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 19.03 million trying to sell their products during the last quarter, with the result yielding a gross income of 12.18 million. This allows shareholders to hold on to 48.71M with the recently reported earning now reading -0.78 cents per share. This is a figure that compared to analyst’s prediction for their 08/05/2021 (-0.78 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.68 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TWST sounds very interesting.
Is the stock of TWST attractive?
In related news, Chief Commercial Officer, Finn Patrick John sold 2,702 shares of the company’s stock in a transaction that recorded on Jun 02. The sale was performed at an average price of 104.64, for a total value of 282,737. As the sale deal closes, the Chief Financial Officer, THORBURN JAMES M now sold 6,000 shares of the company’s stock, valued at 660,000. Also, See Remarks, Banyai William sold 20,275 shares of the company’s stock in a deal that was recorded on May 21. The shares were price at an average price of 96.06 per share, with a total market value of 1,947,657. Following this completion of acquisition, the SVP of Human Resources, Green Paula now holds 490 shares of the company’s stock, valued at 48,334. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.90%.
2 out of 7 analysts covering the stock have rated it a Buy, while 3 have maintained a Hold recommendation on Twist Bioscience Corporation. 1 analysts has assigned a Sell rating on the TWST stock. The 12-month mean consensus price target for the company’s shares has been set at $126.00.
